Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
X4 Pharmaceuticals entered a senior secured term loan facility with K2 HealthVentures totaling up to $150M; $80M funded at closing to repay its prior $75M loan and related fees, with up to $70M additional availability subject to K2HV approval and conditions.
X4 Pharmaceuticals says it completed repayment of an existing loan facility and secured a senior debt facility with K2 HealthVentures of up to $150 million. The company expects to complete enrollment in its Phase 3 4WARD trial by year-end 2026 and deliver topline data in H1 2028.
XFOR says it secured a senior debt facility with K2 HealthVentures with total availability of up to $150 million.